Retifanlimab granted priority review in the US for squamous cell carcinoma of the anal canal (SCAC)

Retifanlimab, an PD-1 inhibitor, will be reviewed for use in this indication specifically for use in patients who have progressed on, or who are intolerant of, platinum-based chemotherapy. The decision to give priority review is based on data from the phase 2 POD1UM-202 trial.

Source:

Biospace Inc.